Breast cancer facts & figures, Am Cancer Soc, 2021, Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed August 4, 2021.

Breast cancer epidemiology and risk factors.

Clin Obstet Gynecol. 59: 651-672

Genetics of breast cancer: a topic in evolution.

Ann Oncol. 26: 1291-1299Valencia O.M. Samuel S.E. Viscusi R.K. et al.

The role of genetic testing in patients with breast cancer: a review.

JAMA Surg. 152: 589-594Keeney M.G. Couch F.J. Visscher D.W. et al.

Non-BRCA familial breast cancer: review of reported pathology and molecular findings.

Pathology. 49: 363-370Economopoulou P. Dimitriadis G. Psyrri A.

Beyond BRCA: new hereditary breast cancer susceptibility genes.

Cancer Treat Rev. 41: 1-8

Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer.

() ()Owens D.K. Davidson K.W. Krist A.H. et al.

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.

JAMA. 322: 652Rajagopal P.S. Nielsen S. Olopade O.I.

USPSTF recommendations for BRCA1 and BRCA2 testing in the context of a transformative national cancer control plan.

JAMA Netw Open. 2: e1910142Daly M.B. Pal T. Berry M.P. et al.

Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.

J Natl Compr Canc Netw. 19: 77-102Gilpin C. Carson N. Hunter A.

A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.

Clin Genet. 58: 299-308Cintolo-Gonzalez J.A. Braun D. Blackford A.L. et al.

Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.

Breast Cancer Res Treat. 164: 263-284Gail M.H. Brinton L.A. Byar D.P. et al.

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

J Natl Cancer Inst. 81: 1879-1886Matsuno R.K. Costantino J.P. Ziegler R.G. et al.

Projecting individualized absolute invasive breast cancer risk in asian and pacific islander american women.

J Natl Cancer Inst. 103: 951-961Gail M.H. Costantino J.P. Pee D. et al.

Projecting individualized absolute invasive breast cancer risk in african american women.

J Natl Cancer Inst. 99: 1782-1792Banegas M.P. John E.M. Slattery M.L. et al.

Projecting Individualized absolute invasive breast cancer risk in US hispanic women.

J Natl Cancer Inst. 109: djw215Adams-Campbell L.L. Makambi K.H. Palmer J.R. et al.

Diagnostic accuracy of the Gail model in the Black Women's Health Study.

Breast J. 13: 332-336Pankratz V.S. Hartmann L.C. Degnim A.C. et al.

Assessment of the accuracy of the Gail model in women with atypical hyperplasia.

J Clin Oncol. 26: 5374-5379Claus E.B. Risch N. Thompson W.D.

Genetic analysis of breast cancer in the cancer and steroid hormone study.

Am J Hum Genet. 48: 232-242

Breast cancer risk-assessment models.

Breast Cancer Res. 9: 213

Assessing risk of breast cancer: a review of risk prediction models.

J Breast Imaging. 3: 144-155Claus E.B. Risch N. Thompson W.D.

Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction.

Cancer. 73: 643-651Parmigiani G. Berry D. Aguilar O.

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Am J Hum Genet. 62: 145-158Mazzola E. Blackford A. Parmigiani G. et al.

Recent enhancements to the genetic risk prediction model BRCAPRO.

Cancer Inform. 14s2: CIN.S17292Antoniou A.C. Pharoah P.D. McMullan G. et al.

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.

Br J Cancer. 86: 76-83Antoniou A.C. Pharoah P.P. Smith P. et al.

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.

Br J Cancer. 91: 1580-1590Valero M.G. Zabor E.C. Park A. et al.

The tyrer–cuzick model inaccurately predicts invasive breast cancer risk in women with LCIS.

Ann Surg Oncol. 27: 736-740Boughey J.C. Hartmann L.C. Anderson S.S. et al.

Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.

J Clin Oncol. 28: 3591-3596Maxwell K.N. Wubbenhorst B. D’Andrea K. et al.

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.

Genet Med. 17: 630-638

Cosgrove J., Genetic services: information on genetic counselor and medical geneticist workforces, In: Office G.A., Online, 2019, United State Government Accountability Office, 1-45, Available at: https://www.gao.gov/assets/gao-20-593.pdf. Accessed January 4, 2022..

Plichta J.K. Sebastian M.L. Smith L.A. et al.

Germline genetic testing: what the breast surgeon needs to know.

Ann Surg Oncol. 26: 2184-2190Hall J.M. Lee M.K. Newman B. et al.

Linkage of early-onset familial breast cancer to chromosome 17q21.

Science. 250: 1684-1689Wooster R. Neuhausen S.L. Mangion J. et al.

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Science. 265: 2088-2090

Supreme Court Decision in Association for Molecular Pathology v. Myriad Genetics, Inc. 2013. Available at: https://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf. Accessed September 11, 2016.

Plichta J.K. Griffin M. Thakuria J. et al.

What's new in genetic testing for cancer susceptibility?.

Oncology (Williston Park). 30: 787-799Welsh J.L. Hoskin T.L. Day C.N. et al.

Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes.

Ann Surg Oncol. 24: 3067-3072Dillon J. Ademuyiwa F.O. Barrett M. et al.

Disparities in genetic testing for heritable solid-tumor malignancies.

Surg Oncol Clin N Am. 31: 109-126Ademuyiwa F.O. Salyer P. Ma Y. et al.

Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.

Breast Cancer Res Treat. 178: 151-159Chapman-Davis E. Zhou Z.N. Fields J.C. et al.

Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center.

J Gen Intern Med. 36: 35-42

Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.

Breast J. 15: S56-S62

Disparities in genetic testing and care among black women with hereditary breast cancer.

Curr Breast Cancer Rep. 12: 125-131Cragun D. Weidner A. Lewis C. et al.

Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.

Cancer. 123: 2497-2505Ademuyiwa F.O. Salyer P. Tao Y. et al.

Genetic counseling and testing in african american patients with breast cancer: a nationwide survey of US breast oncologists.

J Clin Oncol. 39: 4020-4028Eichmeyer J.N. Zuckerman D.S. Beck T.M. et al.

The value of a genetic counselor for patient identification.

J Clin Oncol. 30: 97Pederson H.J. Hussain N. Noss R. et al.

Impact of an embedded genetic counselor on breast cancer treatment.

Breast Cancer Res Treat. 169: 43-46

Daly M.B., Pal T., Arun B., et al., NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2022. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed January 4, 2022.

Bland K.C.E. Klimberg V. Gradishar W.

The breast comprehensive management of benign and malignant diseases.

5th ed. Elsevier, Philadelphia, PA

Breast density implications and supplemental screening.

Eur Radiol. 29: 1762-1777Geisel J. Raghu M. Hooley R.

The role of ultrasound in breast cancer screening: the case for and against ultrasound.

Semin Ultrasound CT MR. 39: 25-34Sung J.S. Lebron L. Keating D. et al.

Performance of dual-energy contrast-enhanced digital mammography for screening women at increased risk of breast cancer.

Radiology. 293: 81-88Vreugdenburg T.D. Willis C.D. Mundy L. et al.

A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis.

Breast Cancer Res Treat. 137: 665-676Yao K. Liederbach E. Tang R. et al.

Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.

Ann Surg Oncol. 22: 370-376Carbine N.E. Lostumbo L. Wallace J. et al.

Risk-reducing mastectomy for the prevention of primary breast cancer.

Cochrane Database Syst Rev. 4: Cd002748Heemskerk-Gerritsen B.A.M. Jager A. Koppert L.B. et al.

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res Treat. 177: 723-733Gahm J. Wickman M. Brandberg Y.

Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery.

Breast. 19: 462-469Jeffers L. Reid J. Fitzsimons D. et al.

Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

Cochrane Database Syst Rev. 10: Cd012894van den Broek A.J. Schmidt M.K. van 't Veer L.J. et al.

Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.

PLoS One. 10: e0120189van den Broek A.J. Schmidt M.K. van 't Veer L.J. et al.

Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients.

Ann Surg. 270: 364-372van den Broek A.J. van 't Veer L.J. Hooning M.J. et al.

Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers.

J Clin Oncol. 34: 409-418Ludwig K.K. Neuner J. Butler A. et al.

Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.

Am J Surg. 212: 660-669Tutt A.N.J. Garber J.E. Kaufman B. et al.

Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.

N Engl J Med. 377: 523-533Robson M. Im S.A. Senkus E. et al.

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.

N Engl J Med. 377: 523-533Litton J.K. Rugo H.S. Ettl J. et al.

Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.

N Engl J Med. 379: 753-763Gradishar W.J. Moran M.S. Abraham J. et al.

NCCN Guidelines: Breast Cancer (version 1.2022) 2021;1.

() ()Berry D.A. Iversen Jr., E.S. Gudbjartsson D.F. et al.

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

J Clin Oncol. 20: 2701-2712Antoniou A.C. Cunningham A.P. Peto J. et al.

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.

Br J Cancer. 98: 1457-1466